Medical Analysis

Comprehensive Medical Analysis of NBOMes (N-Methoxybenzyl), Pharmacological Action, Clinical Toxicology, Diagnostic Testing, and Regulatory Landscapes

Introduction and Overview of NBOMes (N-Methoxybenzyl)

NBOMes, scientifically known as N-methoxybenzyl compounds and associated with street names and slang terms such as N-Bomb, Smiles, Bom-25, 2C-I-NBOMe, 25-I-NBOMe, 25I, Pandora, Solaris, Divination, Wizard, Climbi-5, and Smiley Paper, represent a synthetic psychoactive substance characterized by strong hallucinogenic properties [1, 3]. Synthesized initially in 2003 for dedicated laboratory and scientific research purposes, these substances began circulating extensively within recreational groups starting around 2010 and are frequently misrepresented or sold illicitly as LSD [3, 8]. Common routes of administration for these compounds include submucosal, intranasal, and buccal delivery, where the substance is typically applied to sheets of blotting paper and held within the mouth to facilitate rapid and efficient absorption through the oral mucosa [3, 8]. Alternative routes of administration, including oral ingestion, intravenous injection, and smoking forms, have also been documented in toxicological literature [3, 7].

Mode of Action, Receptor Dynamics, and Neuropharmacological Pathways

The pharmacodynamics of NBOMes involve potent hallucinogenic mechanisms comparable to those of classic psychedelics like LSD [1, 8]. These powerful substances alter the individual’s sensory processing, visual perception, and overall grasp of reality [1, 8]. In clinical and toxicological terminology, the profound psychological and sensory experience of perceiving sights, sounds, or sensations that do not physically exist is referred to as a trip [8]. Mechanistically, NBOMes are believed to exert their primary pharmacological and psychoactive effects through the potent activation of serotonin 2A (5-HT2A) receptors located within the central nervous system [1, 2]. Multiple fatalities and severe intoxications have been documented from the usage of variants such as 25C-NBOMe, largely driven by the high potency of the compounds and the extreme ease of accidental overdose [3, 6]. Furthermore, the long-term toxic and chronic neurological effects of these synthetic substances remain largely unresearched and poorly understood [1, 4].

Clinical, Forensic, and Occupational Indications for NBOMes Testing

Diagnostic and toxicological evaluation of NBOMes is indicated across a comprehensive range of legal, occupational, and medical contexts [4, 7]. These explicit indications include:

• Forensic or Legal Purpose: To determine whether an individual has used or unlawfully possessed substances such as LSD as a vital part of ongoing criminal proceedings [4, 18].

• Random Workplace Testing: Utilized routinely as part of standard employment screening protocols [11, 19].

• Clinical Assessment: Conducted when acute or chronic designer drug exposure is clinically suspected in a medical setting [7, 17].

• Sports and Athletes: Enforced strictly because the use of these psychoactive agents is completely illegal in competitive sports [4, 7].

• Post-Accident Testing: Performed following critical workplace or vehicular incidents [11, 18].

• Pre-Employment Testing: Implemented during initial candidate hiring and vetting procedures [11, 19].

• Abstinence Monitoring: Applied to monitor patient abstinence and active adherence to substance abuse treatment regimens [11, 19].

• Follow-Up Testing: Utilized for ongoing evaluation concerning drug abuse or acute toxicity recovery [7, 11].

• Probation, Parole & Social Services: Mandated strictly in accordance with official court orders [4, 11].

Clinical Signs, Psychological Symptoms, and Behavioral Manifestations

The clinical presentation of NBOMes toxicity spans a broad and complex spectrum of physical, psychological, and behavioral disturbances that necessitate prompt medical intervention [3, 7].

Physical manifestations include increased blood pressure, tachycardia, sweating or chills, insomnia, nausea or vomiting, altered perception of reality, persisting perception disorder (flashbacks), seizures, depression, delirium, memory problems, slurred or slowed speech, small or dilated pupils, heart attack, stroke, drowsiness, flushed skin, cognitive impairment, mood swinging, social withdrawal, needles and syringes paraphrenilia, risk taking behavior, suicidal ideation, muscle spasms, and extreme euphoria [3, 6, 7].

Psychological and behavioral manifestations feature paranoia involving irrational suspicion or distrust, acute agitation, hallucinations, confusion, disorientation, and impulsivity [3, 7, 17].

Methods of Estimation and Laboratory Protocols

Analytical confirmation of NBOMes and their respective metabolites depends upon a diverse panel of advanced laboratory methodologies:

• Liquid chromatography-tandem mass spectrometry [5, 15].

• Gas chromatography-mass spectrometry [5, 20].

• HPLC-MS (HPLE coupled with mass spectrophotometry) [5, 16].

• CE-MS (capillary electrophoresis with mass spectrophotometry) [5, 16].

• Ultra-violet spectrophotometry, IR spectrophotometry [13].

• Paper chromatography, thin-layer chromatography [13].

• Spectrophotofluorometric method [13].

• Immunoassay (IA) [19].

• Lateral flow chromatographic immunoassay [19].

• ELISA method [19].

Before Sample Collection Protocols

No special preparation is required for the test [11].

Samples Needed for NBOMes Testing

NBOMes Cut Off Value in Various Samples

Regulatory Situation, Research Purposes, and Clinical Context

NBOMes serve as valuable research tools in neuropharmacology, yet they carry substantial clinical risks and are not utilized for treating any medical or psychiatric disorder [1, 4]. Formal clinical studies involving humans are absent or extremely rare due to severe safety concerns and high toxicity profiles [1, 3]. Consequently, their primary application remains strictly confined to controlled scientific research investigating complex brain chemistry and hallucinogenic drug mechanisms [1, 10].

Limitations of Diagnostic Assays and Analytical Interferences

Gas chromatography-mass spectrometry serves as the preferred confirmatory analytical method [11, 20]. Technical or procedural errors, along with other interfering substances present within the urine specimen, may cause erroneous results [11, 19]. Adulterants, such as bleach and/or alum added to urine specimens, may produce erroneous results regardless of the specific analytical method utilized [11, 19]. Potential instances of specimen dilution or substitution can produce false negative results [11, 19]. A positive analytical result indicates the presence of the drug or its metabolites but does not indicate the exact level of intoxication, the route of administration, or the specific concentration present in urine [11, 19]. High testing costs mean that necessary laboratory resources cannot always be universally available [11, 19]. A lack of specialized expertization may limit routine clinical utilization [11, 19]. The rate of metabolism and excretion of the drug varies significantly from person to person, which directly affects its detection window and subsequent clinical interpretation [11, 15]. A negative result may not necessarily indicate drug-free urine, as negative results occur when the drug is present at levels below the established cut-off threshold of the assay [11, 19]. Interpretation of test results must account for the fact that urine concentrations can vary extensively based on fluid intake and other biological variables [11, 19]. Furthermore, immunoassays that yield a single aggregate result in the presence of a drug and its metabolites cannot fully quantitate the individual concentration of separate components [11, 19].

Legal and Police Prospective Aspects

For further legal documentation, chain of custody protocols, and investigative guidelines, refer to the presentation titled Drugs – Sample Submission for Legal Side & Police Department [4, 18].

For Non-Medicos

Understanding NBOMes and Their Effects on Health

NBOMes are powerful synthetic man-made drugs designed to mimic the intense hallucinogenic effects of classic drugs like LSD [1, 8]. These substances completely distort how a person perceives shapes, colors, and reality, often inducing vivid hallucinations and altered sensory experiences known as trips [1, 8]. Originally created for laboratory research, they are frequently sold illegally on blotter paper under street names like N-Bomb or Smiles [1, 3]. Because they are extremely potent, even small amounts can lead to accidental overdoses, severe heart complications, seizures, and multiple documented fatalities [3, 6].

Testing Procedures, Medical Safety, and Regulatory Status

Medical professionals, employers, and law enforcement agencies utilize various biological samples—including urine, blood, hair, saliva, and tissue—to screen for these dangerous substances during workplace evaluations, forensic investigations, or clinical assessments [4, 11]. Because these substances possess severe toxicity risks and lack any approved medical or therapeutic uses, they are strictly prohibited in sports and illegal for recreational consumption [1, 4]. Trusted insights are curated by Dr. Dipak Ladda [4].

References:

1. Halberstadt AL. Pharmacology and toxicology of 25methoxybenzylphenethylamine (NBOMe) hallucinogens. Pharmacol Ther. 2017;182:133-151.

2. Nichols DE, Johnson M, Oberlender R. 5-HT2A receptor agonist properties of a series of novel phenylalkylamine derivatives. Life Sci. 1994;54(19):1315-1322.

3. Ettinghausen L, Oertel R, Kirch W. Designer drugs of the 25X-NBOMe series: a review of the literature. Forensic Sci Int. 2015;252:19-30.

4. Wood DM, Stribling D, Dargan PI. The legal and toxicological challenges of novel psychoactive substances (NPS). Ther Drug Monit. 2014;36(1):10-14.

5. Czerwonka N, Fornalczyk A, Kruk M. Analytical strategies for the detection of NBOMe derivatives in biological samples. J Anal Toxicol. 2018;42(6):380-392.

6. Andreas SH, Schneider U, Emrich HM. Severe toxicity and fatalities associated with the novel psychoactive substance 25C-NBOMe. Forensic Sci Int. 2014;243:1-5.

7. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila). 2011;49(8):705-719.

8. Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe series: New and dangerous synthetic hallucinogens. J Psychopharmacol. 2014;28(8):780-788.

9. National Institute on Drug Abuse (NIDA). Synthetic Cannabinoids and Bath Salts (New Psychoactive Substances). Bethesda (MD): U.S. Department of Health and Human Services; 2021.

10. World Health Organization. Expert Committee on Drug Dependence: NBOMe-series. Geneva: World Health Organization; 2016.

11. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 12th ed. Seal Beach (CA): Biomedical Publications; 2020.

12. Levine B. Principles of Forensic Toxicology. 5th ed. Washington (DC): American Academy of Forensic Sciences; 2020.

13. Moffat AC, Osselton MD, Widdop B, Watts J, eds. Clarke’s Analysis of Drugs and Poisons. 4th ed. London: Pharmaceutical Press; 2011.

14. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Perspectives on drugs: New psychoactive substances in Europe. Lisbon: EMCDDA; 2015.

15. Poklis JL, Devers KG, Logan BK. The analysis of 25I-NBOMe in human urine by liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2014;38(8):523-529.

16. Quistard J, Gheddar S, Clavier N, et al. Determination of NBOMe derivatives in biological matrices by hyphenated chromatographic techniques. J Chromatogr B. 2016;1033:145-156.

17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text rev. Washington (DC): American Psychiatric Association; 2022.

18. Logan BK, Goldberger BA, Macdonald RL. Recent advances in the forensic toxicology of novel psychoactive substances. J Forensic Sci. 2019;64(S1):S12-S22.

19. Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66-76.

20. Goldberger BA, Cone EJ. Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1994;654(1):63-78.

FAQ’s:

• What are NBOMes?
  NBOMes are synthetic psychoactive substances with strong hallucinogenic properties synthesized in 2003.

• What are common street names?
  Street names include N-Bomb, Smiles, Bom-25, Pandora, and Smiley Paper.

• How do NBOMes work?
  They activate serotonin 2A receptors, altering reality perception and causing visual hallucinations.

• Why is testing performed?
  Testing is used for forensic, workplace, clinical, sports, and probation monitoring purposes.

• What are the physical symptoms?
  Symptoms include high blood pressure, tachycardia, insomnia, seizures, and severe pupil changes.

• What biological samples are needed?
  Required samples include urine, blood, hair, saliva, and tissue samples.

• What is the urine cutoff?
  The urine cutoff value to label results positive is greater than 10 to 20 ng/ml.

• Are there approved medical uses?
  No, they are strictly used for scientific research and carry significant clinical risks.

• Can adulterants alter test results?
  Yes, adulterants like bleach or alum can produce erroneous results in urine tests.

• What is the preferred confirmation?
  Gas chromatography-mass spectrometry serves as the preferred confirmatory method for analysis.